查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1917894

泌尿系统护理市场－2026-2031年预测

Urologic Care Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 129 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计泌尿系统护理市场将从 2025 年的 222.88 亿美元成长到 2031 年的 349.56 亿美元，复合年增长率为 7.79%。

泌尿系统市场是全球医疗保健领域一个重要且不断发展的细分市场，致力于预防、诊断和治疗影响泌尿系统和男性生殖器官的疾病。市场涵盖医疗设备、药品和治疗服务，涉及多种疾病，包括肾结石、尿道感染、良性前列腺增生、泌尿系统癌症和尿失禁。在人口趋势、技术创新和医疗服务模式变革的驱动下，该市场专注于改善临床疗效、提高患者生活品质并简化泌尿系统手术流程。

推动市场发展的主要强劲动力之一是全球泌尿系统疾病盛行率的上升。这一增长归因于多种因素，包括人口老化（导致良性前列腺增生和泌尿系统癌症等疾病的发病率升高）、生活方式相关的风险因素以及诊断能力的提高，从而提高了疾病检出率。肾结石和復发性尿道感染等常见疾病负担的加重，持续推高了对有效诊断工具、治疗方法和长期管理策略的需求，为已开发经济体和新兴经济体的市场成长奠定了坚实的基础。

市场技术进步的核心在于微创手术（MIS）技术的广泛应用和持续改进。肾结石雷射碎石术、机器人辅助根治性摄护腺切除术和内视镜肿瘤切除术等手术已成为公认的标准治疗方案。与传统开放性手术相比，这些技术具有显着优势，包括减轻术后疼痛、缩短住院时间、加快康復速度以及改善美容效果。这种转变促使并推动了专用设备的创新，包括先进的内视镜系统、雷射平台、机器人手术主机和一次性器械，从而在整个医疗设备业中催生了一个充满活力且竞争激烈的细分领域。

随着手术技术的创新，个人化和精准医疗方法正日益融入泌尿系统实践。这一趋势在肿瘤学领域尤其明显，肿瘤基因组分析被用于指南进行性前列腺癌、膀胱癌和肾癌的治疗方案选择。利用生物标记检测预测疾病进展以及对特定标靶治疗和免疫疗法的反应，可以製定更个人化和有效的治疗方案。这种个人化医疗的趋势不仅限于肿瘤学，考虑患者个别因素以优化治疗效果并最大限度减少副作用的管理策略也正在影响其他疾病领域。

扩大医疗服务覆盖范围和采用以病人为中心的照护模式也在重塑市场格局。数位健康技术，尤其是远端医疗，正被用于远距咨询、追踪护理和慢性病管理，从而改善农村和医疗服务不足地区患者的就医途径，并提升所有患者的就医便利性。此外，人们越来越重视以患者为中心的全面护理，这种护理不仅关注临床症状，还关註生活品质问题，例如维持性功能和泌尿功能。这种方法强调跨领域团队的共同决策，使治疗方案更贴近患者的价值观和偏好。

从地理上看，北美仍然是领先且成熟的市场。这一主导地位得益于泌尿系统疾病的高发病率、完善且技术先进的医疗保健基础设施、对创新疗法有利的报销政策以及众多主要企业的集中。该地区强大的临床研究生态系统也促进了新技术和治疗模式在临床实践中的快速应用。

竞争格局的特点是既有拥有全面泌尿系统产品组合的大型多元化医疗技术公司，也有专注于结石治疗和良性前列腺增生治疗等细分领域的专业公司。关键的竞争策略围绕着雷射技术和机器人平台等领域的技术领先地位、将设备与耗材和软体整合的解决方案的开发，以及证明其卓越疗效和成本效益的可靠临床证据的产生。设备製造商、製药公司和诊断设备製造商之间的策略联盟也十分常见，旨在为前列腺癌等复杂疾病打造综合解决方案。

总之，随着人口结构变化和技术进步的共同作用，泌尿系统市场持续发展演变。结构性因素支撑着市场成长：全球人口老化和泌尿系统疾病盛行率上升。未来市场发展将受到以下因素的影响：内视镜设备的进一步小型化和智慧化、机器人平台在常规手术中的应用、人工智慧在诊断影像和治疗计划中的成功应用，以及个人化治疗方案的不断改进。产业相关人员的成功取决于其能否顺应微创介入、精准医疗和以病人为中心的医疗服务等整体趋势进行创新，并在日益注重成本效益的医疗环境中展现自身价值。

本报告的主要优势：

  • 深入分析：提供对主要和新兴地区的深入市场洞察，重点关注客户群、政府政策和社会经济因素、消费者偏好、行业垂直领域和其他细分市场。
  • 竞争格局：了解全球主要参与者的策略倡议，并了解透过正确的策略进入市场的机会。
  • 市场驱动因素与未来趋势：探讨影响市场的动态因素和关键趋势及其对未来市场发展的影响。
  • 可操作的建议：利用这些见解，在动态环境中做出策略决策，并开拓新的商机和收入来源。
  • 受众广泛：适用于Start-Ups、研究机构、顾问公司、中小企业和大型企业，且经济实惠。

您打算如何使用这份报告？

产业与市场分析、机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法规结构及影响、新产品开发、竞争情报

报告范围：

  • 2021年至2025年的历史数据和2026年至2031年的预测数据
  • 成长机会、挑战、供应链前景、法规结构与趋势分析
  • 竞争定位、策略和市场占有率分析
  • 按业务板块和地区（包括国家）分類的收入和预测评估
  • 公司概况（策略、产品、财务资讯、关键发展等）

目录

第一章执行摘要

第二章 市场概览

  • 市场概览
  • 市场定义
  • 调查范围
  • 市场区隔

第三章 商业情境

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策与法规
  • 策略建议

第四章 技术展望

第五章 依产品类型分類的泌尿系统护理市场

  • 介绍
  • 植入
  • 医疗设备和器械
  • 消耗品

第六章泌尿系统护理市场依应用领域划分

  • 介绍
  • 摄护腺癌
  • 膀胱癌
  • 肾结石
  • 勃起功能障碍
  • 尿失禁
  • 其他的

第七章泌尿系统护理市场（依最终用户划分）

  • 介绍
  • 医院
  • 专科诊所及透析中心
  • 其他的

第八章 各地区泌尿系统医疗市场

  • 介绍
  • 北美洲
    • 依产品类型
    • 透过使用
    • 最终用户
    • 按国家/地区
      • 我们
      • 加拿大
      • 墨西哥
  • 南美洲
    • 依产品类型
    • 透过使用
    • 最终用户
    • 按国家/地区
      • 巴西
      • 阿根廷
      • 其他的
  • 欧洲
    • 依产品类型
    • 透过使用
    • 最终用户
    • 按国家/地区
      • 德国
      • 法国
      • 英国
      • 西班牙
      • 义大利
      • 其他的
  • 中东和非洲
    • 依产品类型
    • 透过使用
    • 最终用户
    • 按国家/地区
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 其他的
  • 亚太地区
    • 依产品类型
    • 透过使用
    • 最终用户
    • 按国家/地区
      • 中国
      • 印度
      • 日本
      • 韩国
      • 印尼
      • 泰国
      • 台湾
      • 其他的

第九章 竞争格局与分析

  • 主要企业和策略分析
  • 市占率分析
  • 合併、收购、协议和合作
  • 竞争对手仪錶板

第十章：公司简介

  • Fresenius Medical Care AG
  • Boston Scientific Corporation
  • Medtronic Plc
  • Olympus Corporation
  • Cook Medical Llc
  • Becton Dickinson
  • Coloplast Group
  • Karl Storz
  • Teleflex Incorporated
  • Stryker Corporation

第十一章附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要收益
  • 调查方法
  • 简称
简介目录
Product Code: KSI061615959

Urologic Care Market is forecasted to rise at a 7.79% CAGR, reaching USD 34.956 billion in 2031 from USD 22.288 billion in 2025.

The urologic care market is a significant and evolving segment of the global healthcare sector, dedicated to the prevention, diagnosis, and management of diseases affecting the urinary system and male reproductive organs. Encompassing medical devices, pharmaceuticals, and therapeutic services, this market addresses a broad range of conditions including kidney stones, urinary tract infections, benign prostatic hyperplasia, urologic cancers, and incontinence. Driven by demographic trends, technological innovation, and a shift in care delivery models, the market is focused on improving clinical outcomes, enhancing patient quality of life, and increasing the efficiency of urologic interventions.

A primary and powerful driver of market evolution is the rising global prevalence of urologic disorders. This increase is attributable to several factors, including aging populations (which elevate the incidence of conditions like prostate enlargement and urologic cancers), lifestyle-related risk factors, and improved diagnostic capabilities leading to higher detection rates. The growing burden of common conditions such as kidney stones and recurrent urinary tract infections creates sustained demand for effective diagnostic tools, treatment modalities, and long-term management strategies, forming a solid foundation for market growth across both developed and emerging economies.

Central to the market's technological advancement is the widespread adoption and continuous refinement of minimally invasive surgical (MIS) techniques. Procedures such as laser lithotripsy for kidney stones, robotic-assisted prostatectomies, and endoscopic tumor resections have become standard of care. These approaches offer demonstrable benefits over traditional open surgery, including reduced postoperative pain, shorter hospital stays, faster recovery, and improved cosmetic outcomes. This shift necessitates and drives innovation in specialized equipment, including advanced endoscopic systems, laser platforms, robotic surgical consoles, and single-use disposable instruments, creating a dynamic and competitive segment within the broader medical device industry.

Parallel to procedural innovation is the increasing integration of personalized and precision medicine approaches into urologic practice. This trend is particularly prominent in oncology, where genomic profiling of tumors guides therapy selection for advanced prostate, bladder, and kidney cancers. The use of biomarker testing to predict disease aggressiveness and response to specific targeted therapies or immunotherapies allows for more tailored and effective treatment plans. This movement toward individualized care extends beyond oncology, influencing management strategies for other conditions by considering patient-specific factors to optimize outcomes and minimize side effects.

The market is also being reshaped by the expansion of healthcare access and the adoption of patient-centric care models. Digital health technologies, particularly telemedicine, are being leveraged to provide remote consultations, follow-up care, and chronic disease management, improving access for patients in rural or underserved areas and enhancing convenience for all. Furthermore, there is a growing emphasis on holistic, patient-focused care that addresses not only the clinical condition but also quality-of-life issues, such as sexual function and continence preservation. This approach involves multidisciplinary teams and shared decision-making, aligning treatment plans more closely with patient values and preferences.

Geographically, North America remains a dominant and mature market. This leadership is supported by a high prevalence of urologic conditions, a well-established and technologically advanced healthcare infrastructure, favorable reimbursement policies for innovative procedures, and a concentration of leading medical device and pharmaceutical companies. The region's robust clinical research ecosystem also facilitates the rapid translation of new technologies and treatment paradigms into clinical practice.

The competitive landscape features large, diversified medical technology corporations with comprehensive urology portfolios, alongside specialized companies focused on niche areas such as stone management or benign prostatic hyperplasia therapy. Key competitive strategies revolve around technological leadership in areas like laser technology and robotic platforms, developing integrated solutions that combine devices with consumables and software, and generating robust clinical evidence to demonstrate superior efficacy and cost-effectiveness. Strategic partnerships between device manufacturers, pharmaceutical companies, and diagnostic firms are also common, aimed at creating comprehensive solutions for complex conditions like prostate cancer.

In conclusion, the urologic care market is advancing through a confluence of demographic necessity and technological progress. Its growth is structurally supported by an aging global population and the increasing burden of urologic disease. Future market development will be shaped by further miniaturization and intelligence of endoscopic devices, the expansion of robotic platforms into more routine procedures, the successful integration of artificial intelligence for diagnostic imaging and procedural planning, and the continued maturation of personalized therapeutic approaches. Success for industry participants will depend on their ability to innovate in alignment with the overarching trends of minimally invasive intervention, precision medicine, and patient-centered care delivery, all while demonstrating value in an increasingly cost-conscious healthcare environment.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Urologic Care Market Segmentation

  • By Product Type
  • Implants
  • Devices & Instruments
  • Consumables
  • By Application
  • Prostate Cancer
  • Bladder Cancer
  • Kidney Stones
  • Erectile Dysfunction
  • Urinary Incontinence
  • Others
  • By End-User
  • Hospitals
  • Specialized Clinics & Dialysis Centers
  • Others
  • By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Taiwan
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. UROLOGIC CARE MARKET BY PRODUCT TYPE

  • 5.1. Introduction
  • 5.2. Implants
  • 5.3. Devices & Instruments
  • 5.4. Consumables

6. UROLOGIC CARE MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Prostate Cancer
  • 6.3. Bladder Cancer
  • 6.4. Kidney Stones
  • 6.5. Erectile Dysfunction
  • 6.6. Urinary Incontinence
  • 6.7. Others

7. UROLOGIC CARE MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Specialized Clinics & Dialysis Centers
  • 7.4. Others

8. UROLOGIC CARE MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Product Type
    • 8.2.2. By Application
    • 8.2.3. By End-User
    • 8.2.4. By Country
      • 8.2.4.1. USA
      • 8.2.4.2. Canada
      • 8.2.4.3. Mexico
  • 8.3. South America
    • 8.3.1. By Product Type
    • 8.3.2. By Application
    • 8.3.3. By End-User
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
      • 8.3.4.2. Argentina
      • 8.3.4.3. Others
  • 8.4. Europe
    • 8.4.1. By Product Type
    • 8.4.2. By Application
    • 8.4.3. By End-User
    • 8.4.4. By Country
      • 8.4.4.1. Germany
      • 8.4.4.2. France
      • 8.4.4.3. United Kingdom
      • 8.4.4.4. Spain
      • 8.4.4.5. Italy
      • 8.4.4.6. Others
  • 8.5. Middle East and Africa
    • 8.5.1. By Product Type
    • 8.5.2. By Application
    • 8.5.3. By End-User
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
      • 8.5.4.2. UAE
      • 8.5.4.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. By Product Type
    • 8.6.2. By Application
    • 8.6.3. By End-User
    • 8.6.4. By Country
      • 8.6.4.1. China
      • 8.6.4.2. India
      • 8.6.4.3. Japan
      • 8.6.4.4. South Korea
      • 8.6.4.5. Indonesia
      • 8.6.4.6. Thailand
      • 8.6.4.7. Taiwan
      • 8.6.4.8. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Fresenius Medical Care AG
  • 10.2. Boston Scientific Corporation
  • 10.3. Medtronic Plc
  • 10.4. Olympus Corporation
  • 10.5. Cook Medical Llc
  • 10.6. Becton Dickinson
  • 10.7. Coloplast Group
  • 10.8. Karl Storz
  • 10.9. Teleflex Incorporated
  • 10.10. Stryker Corporation

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key Benefits for the Stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations